Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 130, Issue 1, 2013, Pages 12-18

  Landrum, Lisa M ^a   Java, James ^b   Mathews, Cara A ^a   Lanneau Jr , Grainger S ^c   Copeland, Larry J ^d   Armstrong, Deborah K ^e   Walker, Joan L ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Epithelial ovarian cancer; Intraperitoneal chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; HISTOLOGY; HUMAN; INTESTINE RESECTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TUMOR VOLUME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, PARENTERAL; LYMPHATIC METASTASIS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84879097208     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.04.001     Document Type: Article

References (26)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. S.A. Cannistra Cancer of the ovary N Engl J Med 351 2004 2519 2529
3. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
4. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
5. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O'Toole, S.D. Williams, and J.A. Young Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 1996 1950 1955
6. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, and L.F. Carson Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 2001 1001 1007
7. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
8. R.L. Dedrick, and M.F. Flessner Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure J Natl Cancer Inst 89 1997 480 487
9. G. Los, P.H. Mutsaers, M. Ruevekamp, and J.G. McVie The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat Cancer Lett 51 1990 109 117
10. D. Collett Modeling survival data in medical research 2003
11. J.L. Walker, D.K. Armstrong, H.Q. Huang, J. Fowler, K. Webster, and R.A. Burger Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study Gynecol Oncol 100 2006 27 32
12. S.A. Cannistra Intraperitoneal chemotherapy comes of age N Engl J Med 354 2006 77 79
13. W.J. Hoskins The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer Baillieres Clin Obstet Gynaecol 3 1989 59 71
14. W.J. Hoskins, W.P. McGuire, M.F. Brady, H.D. Homesley, W.T. Creasman, and M. Berman The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 1994 974 979
15. G.A. Omura, M.F. Brady, H.D. Homesley, E. Yordan, F.J. Major, and H.J. Buchsbaum Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience J Clin Oncol 9 1991 1138 1150
16. T. Thigpen, M.F. Brady, G.A. Omura, W.T. Creasman, W.P. McGuire, and W.J. Hoskins Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience Cancer 71 1993 606 614
17. W.J. Hoskins, B.N. Bundy, J.T. Thigpen, and G.A. Omura The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 47 1992 159 166
18. W.E. Winter III, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, and P.G. Rose Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 25 2007 3621 3627
19. L.R. Duska, Y.C. Chang, C.E. Flynn, A.H. Chen, A. Goodman, and A.F. Fuller Epithelial ovarian carcinoma in the reproductive age group Cancer 85 1999 2623 2629
20. J.K. Chan, V. Loizzi, Y.G. Lin, Osann K. Brewster WR, and P.J. DiSaia Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol 102 2003 156 161
21. J.K. Chan, R. Urban, M.K. Cheung, K. Osann, J.Y. Shin, and A. Husain Ovarian cancer in younger vs older women: a population-based analysis Br J Cancer 95 2006 1314 1320
22. B.A. Goff, R. Sainz de la Cuesta, H.G. Muntz, D. Fleischhacker, M. Ek, and L.W. Rice Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease Gynecol Oncol 60 1996 412 417
23. V. Hess, R. A'Hern, N. Nasiri, D.M. King, P.R. Blake, and D.P. Barton Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment J Clin Oncol 22 2004 1040 1044
24. J.I. Akahira, H. Yoshikawa, Y. Shimizu, R. Tsunematsu, T. Hirakawa, and H. Kuramoto Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study Gynecol Oncol 81 2001 398 403
25. A.P. Makar, M. Baekelandt, C.G. Trope, and G.B. Kristensen The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer Gynecol Oncol 56 1995 175 180
26. D.S. Chi, E.L. Eisenhauer, J. Lang, J. Huh, L. Haddad, and N.R. Abu-Rustum What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103 2006 559 564 Group Administrative Office